Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Ivermectin Use in Humans: Evidence-Based Assessment

COVID-19 Evidence and Recommendations

  • The Infectious Diseases Society of America (IDSA) explicitly recommends against ivermectin use for COVID-19, with a conditional recommendation against use for hospitalized patients (very low certainty of evidence) and a strong recommendation against use for ambulatory persons (moderate certainty of evidence) 1, 2
  • The IDSA notes that in vitro activity against SARS-CoV-2 requires concentrations considerably higher than achievable in human plasma and lung tissue, and clinical trials showed no consistent benefit for COVID-19 treatment 1, 2

Safety Considerations

  • Higher doses of ivermectin potentially needed for non-approved uses may cause significant adverse effects, according to the Infectious Diseases Society of America 1